Ticker
EBSCompany Name
EMERGENT BIOSOLUTIONS INCSector
HealthcareIndustry
Drug Manufacturers - Specialty & GenericExchange
NYSEDate | Capital Expenditure | Capital Expenditures to Operating Cash Flow | Net Cash Flow - Operations |
---|---|---|---|
6/30/2025 | $ -32.1M | 0% | $ 169M |
3/31/2025 | $ -30.3M | 0% | $ 110.1M |
12/31/2024 | $ 15M | 25.55% | $ 58.7M |
9/30/2024 | $ 25M | 14.65% | $ 170.7M |
6/30/2024 | $ 39.4M | 51.17% | $ 77M |
3/31/2024 | $ 47.3M | 0% | $ -84.9M |
12/31/2023 | $ 51.6M | 0% | $ -206.3M |
9/30/2023 | $ 63.8M | 0% | $ -145.6M |
6/30/2023 | $ 79.1M | 0% | $ -279.6M |
3/31/2023 | $ 98.7M | 0% | $ -180.8M |
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
CapEx / CF - Operations
(=) CapEx/OCF
CapEx/OCF for EMERGENT BIOSOLUTIONS INC is calculated as follows: CapEx [ $ 141.1M ] / CF - Operations [ $ 413M ]
(=) CapEx/OCF [ 34.16% ]
Minimum
Sep 30, 2024
Maximum
Sep 30, 2021
Average
Median
filtered constituents | 2.35K |
---|---|
min | 0.01% |
max | 128% |
average | 31.8% |
median | 22.41% |
std | 29.52% |